Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Published:2023-02-21 Issue:4 Volume:7 Page:644-648
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Girgis Suzette¹,Wang Lin Shun Xin¹^ORCID,Pillarisetti Kodandaram¹,Verona Raluca¹,Vieyra Diego¹,Casneuf Tineke²,Fink Damien¹,Miao Xin¹,Chen Yang¹,Stephenson Tara¹,Banerjee Arnob¹,Hilder Brandi W.¹,Russell Jeffery¹,Infante Jeffrey¹,Elsayed Yusri¹,Smit Jennifer¹,Goldberg Jenna D.¹

Affiliation:

1. 1Janssen Research & Development, LLC, Spring House, PA

2. 2Janssen Research & Development, LLC, Beerse, Belgium

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/4/644/2036115/blooda_adv-2022-007625-main.pdf

Reference22 articles.

1. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches;Shah;Leukemia,2020

2. Expression of myeloma cell and soluble B-cell maturation antigen (BCMA) in relapsed and refractory multiple myeloma patients treated with GSK2857916 in BMA117159;Dettman;Blood,2018

3. Bispecific T-cell engagers for cancer immunotherapy;Huehls;Immunol Cell Biol,2015

4. Robust isolation of malignant plasma cells in multiple myeloma;Frigyesi;Blood,2014

5. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma;Atamaniuk;Eur J Clin Invest,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement;Expert Opinion on Biological Therapy;2024-09

2. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies;The Lancet Haematology;2024-09

3. Immunotherapy: the teclistamab fitness test;Blood;2024-08-08

4. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study;Blood;2024-08-08

5. Deciphering the genetics and mechanisms of predisposition to multiple myeloma;Nature Communications;2024-08-05